AlphaBIZ - 종근당이 노바티스에 기술수출한 차세대 항암제 후보물질 ′CKD-510′이 미국에서 임상시험에 본격 돌입한다. 이에 따라 종근당은 첫 기술료를 수령하게 됐다. 종근당은 노바티스에 기술수출한 CKD-510의 단계별 마일스톤 달성에 따라 기술료를 수령할 예정이라고 22일 밝혔다. 마일스톤은 약 69억원(500만달러) 수준이다. 이번 마일스톤은 노바티스가 CKD-510에 대해 미국 식품의약국(FDA)에 첫 번째 임상시험계획서(IND)를 제출한 데

Chong Kun Dang. (Image: Chong Kun Dang)

 

 

[Alpha Biz= Kim Jisun] Chong Kun Dang announced on May 22 that it has received its first milestone payment following the initiation of clinical trials for CKD-510, a next-generation anticancer drug candidate out-licensed to Novartis.



The milestone, valued at approximately KRW 6.9 billion (USD 5 million), was triggered by Novartis’ submission of an Investigational New Drug (IND) application for CKD-510 to the U.S. Food and Drug Administration (FDA). The specific indication for the trial has not yet been disclosed.



CKD-510 is a selective HDAC6 (histone deacetylase 6) inhibitor. Chong Kun Dang signed a licensing agreement with Novartis in November 2023, which included an upfront payment exceeding KRW 100 billion and a total deal value of up to KRW 1.73 trillion, including development and sales-based milestone payments.



This milestone achievement marks the first visible progress since the out-licensing agreement, helping to alleviate concerns about potential discontinuation or return of the licensed asset.



Chong Kun Dang stated, “We are pleased to see the advancement of CKD-510 into clinical trials and look forward to continued progress through our collaboration with Novartis.”

 

 

 

AlphaBIZ Kim Jisun(stockmk2020@alphabiz.co.kr)